Core Viewpoint - Visionary Holdings Inc. has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025 [1][3]. Group 1: Compliance and Reporting - The company was previously notified by Nasdaq on August 5, 2025, regarding non-compliance due to the delayed filing of its Annual Report [2]. - The filing of Form 20-F on January 28, 2026, led to Nasdaq confirming the company's compliance with listing requirements [3]. - Nasdaq informed the company on January 29, 2026, that the compliance matter is now closed [3]. Group 2: Company Overview - Visionary Holdings Inc. is a technology-driven multinational enterprise listed on Nasdaq, focusing on innovative education, AI applications, and high-tech healthcare solutions [4]. - The company is headquartered in Toronto, Canada, and operates through subsidiaries across North America and Asia [4].

Core Insights - Visionary Holdings Inc. has appointed Ms. Wenxuan Cai as the CEO of its subsidiary, Visionary Health Technology Group Limited in Hong Kong, effective immediately [1] - The company has established a new wholly owned subsidiary in Nanjing, China, focusing on sales execution and market development, marking a shift from strategic positioning to active revenue generation [2] Leadership and Market Strategy - Ms. Cai brings nearly two decades of experience in market expansion and sales organization building, particularly in the healthcare sector, and will focus on enhancing sales infrastructure and execution [3][8] - The Nanjing entity will serve as a frontline commercial platform for regional sales operations, completing a fully integrated commercial structure alongside the Hong Kong platform [4] Commercialization Efforts - The company has transitioned from conceptual planning to operational commercialization, with a strong emphasis on building high-performance sales teams and translating market strategies into commercial results [5][6] - Recent milestones include strategic entry into cellular rejuvenation and aesthetic treatment markets, completion of global technology licensing, and the launch of a diversified product portfolio [9] Growth Potential - With leadership, products, and sales infrastructure aligned, the company is well-positioned to capitalize on the growing demand for advanced cellular-based and aesthetic solutions across Asia [7]